drugset / Trial / NCT01324323

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

NCT01324323

Phase 1 Completed 14 enrolled Celgene Corporation
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the effect and safety of multiple doses of rifampin on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.

Timeline

Start
2011-04-01
Primary completion
2012-02-01
Completion
2012-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampin Small molecule 600 mg Oral
Subject Romidepsin Peptide 14 mg/m2 Intravenous

Indications